Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PROC | P04070 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802033 | 0.81 | F10 (0.60) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5800493 | 0.81 | F10 (0.60) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5912962 | 0.81 | F10 (0.60) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5800971 | 0.80 | F10 (0.46) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5800482 | 0.74 | F10 (0.53) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5802903 | 0.74 | F10 (0.53) | F10PRSS1PLGPROCF2 | |
| SCHEMBL5803022 | 0.70 | F10 (0.61) | F10PRSS1PLGPROCF2 | |
| SCHEMBL6372823 | 0.68 | F10 (0.53) | F10PRSS1PLGPROCF2 | |
| SCHEMBL6807634 | 0.67 | F10 (0.75) | F10PRSS1PLGPROCPRSS2 | |
| SCHEMBL6713819 | 0.65 | IMPDH2 (0.47) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | TFPI, TFPI2, F12 | F10 10/4885PRSS1 171/4885PLG 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.